Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Breckenridge

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Hepatology Communications|June 23, 2022
Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosisArchana Vijayakumar, Ayse Okesli-Armlovich, Ting Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 20, 2016
Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β-dependent mechanismsXiarong Shi, Valia T Mihaylova, Leena Kuruvilla, et al.
Biomedicines|January 13, 2021
The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH ModelPhilipp Schwabl, Eva Hambruch, Grant R Budas, et al.
Journal of Hepatology|May 8, 2020
Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activationJamie Bates, Archana Vijayakumar, Sarani Ghoshal, et al.
Cell Reports|November 14, 2019
Single-Cell Transcriptomics Uncovers Zonation of Function in the Mesenchyme during Liver FibrosisRoss Dobie, John R Wilson-Kanamori, Beth E P Henderson, et al.
Science Translational Medicine|October 20, 2021
Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensorsSophie C Cazanave, Andrew D Warren, Maciej Pacula, et al.
The Journal of Clinical Investigation|July 20, 2018
ASK1 contributes to fibrosis and dysfunction in models of kidney diseaseJohn T Liles, Britton K Corkey, Gregory T Notte, et al.
Bioorganic & Medicinal Chemistry|January 5, 2019
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitorDavid Sperandio, Vangelis Aktoudianakis, Kerim Babaoglu, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Hepatology Communications|June 23, 2022
Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosisArchana Vijayakumar, Ayse Okesli-Armlovich, Ting Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 20, 2016
Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β-dependent mechanismsXiarong Shi, Valia T Mihaylova, Leena Kuruvilla, et al.
Biomedicines|January 13, 2021
The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH ModelPhilipp Schwabl, Eva Hambruch, Grant R Budas, et al.
Journal of Hepatology|May 8, 2020
Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activationJamie Bates, Archana Vijayakumar, Sarani Ghoshal, et al.
Cell Reports|November 14, 2019
Single-Cell Transcriptomics Uncovers Zonation of Function in the Mesenchyme during Liver FibrosisRoss Dobie, John R Wilson-Kanamori, Beth E P Henderson, et al.
Science Translational Medicine|October 20, 2021
Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensorsSophie C Cazanave, Andrew D Warren, Maciej Pacula, et al.
The Journal of Clinical Investigation|July 20, 2018
ASK1 contributes to fibrosis and dysfunction in models of kidney diseaseJohn T Liles, Britton K Corkey, Gregory T Notte, et al.
Bioorganic & Medicinal Chemistry|January 5, 2019
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitorDavid Sperandio, Vangelis Aktoudianakis, Kerim Babaoglu, et al.
Pageof 4